Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 325, pseudogene (RNU6-325P) is a processed pseudogene of the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a core non-coding RNA component of the spliceosome, essential for pre-mRNA splicing in eukaryotes[3][5]. However, as a pseudogene, RNU6-325P does not produce a functional RNA molecule and is thought to lack biological function[1][4]. Pseudogenes such as RNU6-325P arise via duplication or retrotransposition and typically are non-functional remnants; they are numerous in the human genome and usually do not encode protein or exert regulatory effects[1][3][4]. While recent research has shown that some RNA pseudogenes can participate in regulatory networks or disease processes, this is specific to only a subset and there is no current evidence linking RNU6-325P itself to any direct biological function, disease association, or therapeutic targeting[1][2]. Thus, RNU6-325P is not considered a receptor, enzyme, transporter, or pharmacological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 325, pseudogene (RNU6-325P).